spike protein Articles
-
Revealing the Details of Changes in Spike Proteins of SARS-CoV-2 Omicron Mutant Strains
The interesting SARS-CoV-2 omicron mutant strain evades immunity mediated by antibodies from vaccination or infection with early mutants due to the accumulation of a large number of spike mutations. Recently, in a research report titled "Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement" published in Science, scientists from institutions such as the University of ...
-
A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity
Self-amplifying RNA vaccines may induce equivalent or more potent immune responses at lower doses compared to non-repli- cating mRNA vaccines via amplified antigen expression. In this paper, we demonstrate that 1 mg of an LNP-formulated dual- antigen self-amplifying RNA vaccine (ZIP1642), encoding both the S-RBD and N antigen, elicits considerably higher neutral- izing antibody titers against ...
-
The Molecular Microbiology of SARS-CoV-2: Detection Methods and Infection Mechanism
SARS-CoV-2 is a newly discovered human coronavirus group (HCoV), which are single-stranded RNA viruses belonging to the family of Coronaviridae. A range of respiratory diseases have been induced by some of these pathogens in the past. SARS-CoV-1 infected more than 8,000 individuals around the world, for example. Human coronavirus linked to Middle East respiratory syndrome (MERS-CoV) also occurred ...
By CD Genomics
-
AI Designed Mutation Resistant Broad Neutralization Antibodies Against Multiple SARS-CoV-2 Strains based on A Digital Twin of COVID-19 - Case study
Introduction The emerging variants including Delta and Omicron may not retain activity with current available mAb products that were developed during the initial outbreak with the B.l strain. In this study, we have applied AI technologies in the computational design of broad neutralization antibodies against over 1300 different historical SARS-CoV-2 strains with very small computational cost. ...
-
Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing
Soon after the genetic sequence of SARS-CoV-2 was determined in January 2020, there was a rush to develop rapid diagnostics for the disease. The World Health Organization issued early guidance and protocols for the use of PCR to assist in diagnosing the disease. However, drawbacks like long turnaround times and invasive sampling for PCR tests led to a concerted push to develop rapid antibody ...
-
Ideal COVID-19 Vaccine May Come from Alpacas, New Study Found
In response to the COVID-19 caused by the new coronavirus (SARS-CoV-2), there are currently many vaccines on the market worldwide. However, despite the fact that major manufacturers are working hard to produce vaccines, the speed of vaccination still cannot keep up with people's needs. At the same time, with the continuous emergence of mutant strains, the effectiveness of vaccines has begun to ...
By Profacgen
-
The Significance of Raw Enzymes in the Success of mRNA Vaccines
In the ever-evolving landscape of global healthcare, mRNA vaccines have emerged as an excellent tool in the fight against infectious diseases. This article explores the intricate and indispensable role that raw enzymes play in the manufacturing of mRNA vaccines, delving deep into their significance and impact on vaccine production. As we venture into this fascinating world, we will gain a ...
-
Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations
Abstract Messenger RNA (mRNA) based vaccines (Pfizer/BioNTech and Moderna) are highly effective at providing immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is uncertainty about the duration of immunity, evolution of IgG antibody levels and IgG avidity (an index of antibody-antigen binding strength), and differences in the immune responses between ...
-
Coronavirus: continued updates in basic research, vaccine development and testing
Researchers have delved further into our understanding of coronavirus, while the race to develop a vaccine continues. New advances in coronavirus understanding New research has put paid to some of the conspiracy theories surrounding coronavirus. A team comprising researchers from both the US, Australia and the UK has analyzed the receptor-binding domain (RBD) and the cleavage site present on ...
-
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine
MADISON, Wis.–(BUSINESS WIRE)–An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu. UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccineTweet this CoroFlu will build on the ...
By FluGen, Inc.
-
Using AI to Fight a Pandemic: Insilico Medicine Announces Novel Preclinical Candidate for COVID-19 Treatment
Insilico Medicine announced the nomination of a novel preclinical therapeutic candidate for treating COVID-19, designed using the generative chemistry AI platform Chemistry42. The new drug candidate is a 3CL protease inhibitor unique from existing drugs in its class because it can be rapidly produced. While this nomination is a potentially important development for the ongoing COVID-19 pandemic ...
-
AlphaFold - The AI Leader in Protein Structure Prediction
In this final installment of our AlphaFold series, we will tell the story of how DeepMind, a research developer in the AI community, leveraged its AlphaFold system to play a vital role in the fight against ...
-
Coronavirus Variants: The Delta Variant and the Future Impact of Viral Mutations
If you are fully vaccinated, should you be worried about the impact of COVID-19 variants? No, in fact vaccines have been shown to be highly effective at preventing hospitalizations and deaths from these SARS-CoV-2 variants. While the infamous Delta variant has now been detected in 98 countries and all 50 states, 99% of all COVID-19 deaths and hospitalization cases are unvaccinated, according to ...
-
Peptide Vaccine Design
Vaccines are considered one of the most successful medical interventions in the past few centuries, aiming to harness the human immune system and generate lasting protection against specific diseases. Traditional vaccines rely on the use of inactivated pathogens to trigger an immune response. However, many of these formulations carry a high risk of causing allergies or autoimmune reactions. ...
-
Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2
The recent COVID-19 pandemic again highlighted the urgent need for broad-spectrum antivirals, both for therapeutic use in acute viral infection and for pandemic preparedness in general. The targeting of host cell factors hijacked by viruses during their replication cycle presents one possible strategy for development of broad-spectrum antivirals. By inhibiting the Raf/MEK/ERK signaling pathway, ...
-
Omicron and Covid-19 Testing: What Healthcare Providers Need to Know
As the SARS-CoV-2 omicron variant (B.1.1.529) rapidly became the dominant strain in South Africa in late 2021, public health officials around the globe recognized that a new, highly transmissible form of the virus was likely emerging.1,2 However, understanding the specifics of what was different about omicron remained to be seen. Beyond higher transmissibility, questions around disease ...
-
New structural target against COVID-19
A new structural target for drug development against COVID-19 has been unveiled today by Sibylla Biotech in collaboration with the Italian National Institute of Nuclear Physics (INFN), the University of Trento and University of Perugia.The breakthrough drug discovery strategy pioneered by Sibylla in this study would not only promise to reduce the risk of drug resistance and harmful side effects, ...
-
COVID-19: It’s Not Over Yet
It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the scientific world and public health communities all came together to identify the cause of this outbreak, to understand the type of “virus” infecting people and identify the infectious ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you